Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer

While HDAC inhibitors have shown promise in hematologic cancers, their efficacy remains limited in solid cancers. In the present study, we evaluated the immunomodulatory properties of the HDAC6 inhibitor, Citarinostat (ACY241) on lung tumor immune compartment and its therapeutic potential in combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Bag, Arup, Schultz, Andrew, Bhimani, Saloni, Stringfield, Olya, Dominguez, William, Mo, Qianxing, Cen, Ling, Adeegbe, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865306/
https://www.ncbi.nlm.nih.gov/pubmed/35223194
http://dx.doi.org/10.1080/2162402X.2022.2042065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865306/
https://www.ncbi.nlm.nih.gov/pubmed/35223194
http://dx.doi.org/10.1080/2162402X.2022.2042065

Ejemplares similares